Avalo Therapeutics, Inc.
AVTXNASDAQHealthcare● Active
$12.73
$-0.37(-2.82%)
Market Cap$143774109
P/E Ratio—
52W High$24.27
52W Low$4.06
Avalo Therapeutics, Inc. (AVTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.06M | $0.44M | $1.92M | $18.05M | $5.40M |
| Cost of Revenue | $0.00M | ($0.37M) | $1.28M | $3.43M | $1.49M |
| Gross Profit | $0.06M | $0.81M | $0.64M | $14.62M | $3.91M |
| Gross Margin %(computed) | 100.00% | 182.99% | 33.26% | 80.98% | 72.38% |
| Operating Expenses | |||||
| R&D Expenses | $50.08M | $52.08M | $13.78M | $31.31M | $59.84M |
| G&A Expenses | $22.43M | $16.45M | $10.27M | $20.64M | $23.00M |
| Total Operating Expenses | $72.98M | $69.32M | $27.99M | $52.06M | $86.04M |
| Operating Income | ($72.92M) | ($68.51M) | ($27.35M) | ($37.44M) | ($82.13M) |
| Operating Margin %(computed) | — | — | — | -207.41% | — |
| Interest Income | $0.00M | $3.32M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $3.42M | $4.17M | $2.39M |
| Income Before Tax | ($78.09M) | ($35.02M) | ($31.53M) | ($41.63M) | ($84.55M) |
| Income Tax Expense | $0.17M | $0.11M | $0.01M | $0.03M | ($0.20M) |
| Net Income | ($78.26M) | ($35.13M) | ($31.54M) | ($41.66M) | ($84.38M) |
| Net Margin %(computed) | — | — | — | -230.78% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.84 | $-4.32 | $-113.58 | $-1062.65 | $-2330.66 |
| Wtd Avg Shares | 13.40M | 8.13M | 0.28M | 0.04M | 0.04M |
| EBITDA | ($72.58M) | ($68.34M) | ($23.29M) | ($37.27M) | ($80.48M) |
| EBITDA Margin %(computed) | — | — | — | -206.49% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Avalo Therapeutics, Inc. data
About Avalo Therapeutics, Inc. (AVTX) Income Statement
Avalo Therapeutics, Inc. (AVTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AVTX reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.08B) — a net profit margin of -132642.37%.
Frequently asked questions
AVTX · 4 questionsAvalo Therapeutics, Inc. (AVTX) reported revenue of $0.00B for 2025, down 86.6% year-over-year.
AVTX revenueAVTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08